Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands.
Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Int J Mol Sci. 2023 Apr 6;24(7):6822. doi: 10.3390/ijms24076822.
Fibrodysplasia Ossificans Progressiva (FOP) is a very rare genetic disease characterized by progressive heterotopic ossification (HO) of soft tissues, leading to immobility and premature death. FOP is caused by a mutation in the Activin receptor Type 1 (ACVR1) gene, resulting in altered responsiveness to Activin-A. We recently revealed that Activin-A induces fewer, but larger and more active, osteoclasts regardless of the presence of the mutated ACVR1 receptor. The underlying mechanism of Activin-A-induced changes in osteoclastogenesis at the gene expression level remains unknown. Transcriptomic changes induced by Activin-A during osteoclast formation from healthy controls and patient-derived CD14-positive monocytes were studied using RNA sequencing. CD14-positive monocytes from six FOP patients and six age- and sex-matched healthy controls were differentiated into osteoclasts in the absence or presence of Activin-A. RNA samples were isolated after 14 days of culturing and analyzed by RNA sequencing. Non-supervised principal component analysis (PCA) showed that samples from the same culture conditions (e.g., without or with Activin-A) tended to cluster, indicating that the variability induced by Activin-A treatment was larger than the variability between the control and FOP samples. RNA sequencing analysis revealed 1480 differentially expressed genes induced by Activin-A in healthy control and FOP osteoclasts with (adj) < 0.01 and a Log2 fold change of ≥±2. Pathway and gene ontology enrichment analysis revealed several significantly enriched pathways for genes upregulated by Activin-A that could be linked to the differentiation or function of osteoclasts, cell fusion or inflammation. Our data showed that Activin-A has a substantial effect on gene expression during osteoclast formation and that this effect occurred regardless of the presence of the mutated ACVR1 receptor causing FOP.
进行性骨化性纤维发育不良(FOP)是一种非常罕见的遗传性疾病,其特征为软组织进行性异位骨化(HO),导致活动受限和过早死亡。FOP 是由激活素受体 1 型(ACVR1)基因突变引起的,导致对激活素-A 的反应改变。我们最近揭示,无论存在突变的 ACVR1 受体,激活素-A 都会诱导更少但更大且更活跃的破骨细胞。在基因表达水平上,激活素-A 诱导破骨细胞生成的变化的潜在机制尚不清楚。使用 RNA 测序研究了来自健康对照者和患者来源的 CD14阳性单核细胞的激活素-A 在破骨细胞形成过程中诱导的基因表达谱变化。从 6 名 FOP 患者和 6 名年龄和性别匹配的健康对照者中分离出 CD14阳性单核细胞,在不存在或存在激活素-A 的情况下分化为破骨细胞。在培养 14 天后分离 RNA 样本并进行 RNA 测序分析。非监督主成分分析(PCA)表明,来自相同培养条件(例如,无或有激活素-A)的样本倾向于聚类,这表明激活素-A 处理引起的可变性大于对照和 FOP 样本之间的可变性。RNA 测序分析显示,在健康对照者和 FOP 破骨细胞中,有 1480 个基因受激活素-A诱导,差异表达(adj)<0.01,Log2 倍数变化≥±2。通路和基因本体论富集分析显示,激活素-A 上调的基因有几个显著富集的通路,这些通路可能与破骨细胞的分化或功能、细胞融合或炎症有关。我们的数据表明,激活素-A 在破骨细胞形成过程中对基因表达有显著影响,并且这种影响发生在存在导致 FOP 的突变型 ACVR1 受体的情况下。